Can-Fite BioPharma (CANF) Retained Earnings (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Retained Earnings came in at -$176.2 million in Q4 2025, down 5.91% YoY from -$187.3 million in Q4 2024, and down 2.89% on a QoQ basis from -$171.2 million in Q2 2025.
Can-Fite BioPharma (CANF) Retained Earnings (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 13 years of Retained Earnings data on file, last reported at -$176.2 million in Q4 2025.
- Quarterly Retained Earnings fell 5.91% year-over-year to -$176.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$176.2 million (down 5.91% YoY) and the FY2025 annual result came in at -$176.2 million, down 5.91% from the prior year.
- Retained Earnings retreated to -$176.2 million in Q4 2025, from -$171.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$127.3 million in Q1 2021 to a low of -$176.2 million in Q4 2025.
- A 5-year average of -$151.2 million and a median of -$152.1 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings retreated 12.38% — and 2024, when it declined 4.75%.
- Tracing CANF's Retained Earnings over 5 years: stood at -$140.7 million in 2021, then slipped by 7.23% to -$150.8 million in 2022, then dropped by 5.06% to -$158.5 million in 2023, then decreased by 4.97% to -$166.4 million in 2024, then fell by 5.91% to -$176.2 million in 2025.
- The last three Retained Earnings figures came in at -$176.2 million (Q4 2025), -$171.2 million (Q2 2025), and -$166.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | -176.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -176.19 Mn |
| Jun 30, 2025 | -171.24 Mn |
| Dec 31, 2024 | -166.36 Mn |
| Jun 30, 2024 | -162.44 Mn |
| Dec 31, 2023 | -158.48 Mn |
| Sep 30, 2023 | -156.83 Mn |
| Jun 30, 2023 | -155.07 Mn |
| Mar 31, 2023 | -153.40 Mn |
| Dec 31, 2022 | -150.85 Mn |
| Sep 30, 2022 | -147.83 Mn |
| Jun 30, 2022 | -145.30 Mn |
| Mar 31, 2022 | -143.11 Mn |
| Dec 31, 2021 | -140.67 Mn |
| Sep 30, 2021 | -133.97 Mn |
| Jun 30, 2021 | -130.57 Mn |
| Mar 31, 2021 | -127.35 Mn |
| Dec 31, 2020 | -125.47 Mn |
| Jun 30, 2020 | -119.26 Mn |
| Dec 31, 2019 | -110.31 Mn |
| Sep 30, 2019 | -108.46 Mn |